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Abstract Gabapentin (GBP) is a Q-aminobutyric acid analog
e¡ective in the treatment of seizures. A high-a⁄nity interaction
between GBP and the K2N subunit of the voltage-gated Ca2
+
channels has been documented. In this report, we examined the
e¡ects of the chronic treatment with GBP on neuronal recombi-
nant P/Q-type Ca2+ channels expressed in Xenopus oocytes.
GBP did not a¡ect signi¢cantly the amplitude or the voltage
dependence of the currents. Exposure to the drug did, however,
slow down the kinetics of inactivation in a dose-dependent fash-
ion. In addition, biochemical analysis showed that the integrity
of Ca2+ channel complex is not apparently a¡ected by GBP
binding, suggesting that chronic treatment with the drug might
cause the channel kinetic modi¢cation through subtle conforma-
tional changes of the protein complex. , 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
The in£ux of Ca2þ ions through voltage-gated Ca2þ chan-
nels contributes to neuronal excitability and is an important
feature of epileptogenesis. Ca2þ channels contribute signi¢-
cantly to the depolarization shift seen in focal epilepsy and
are also implicated in the increase of excitability during the
transition to seizures and in the spread of seizure activity [1].
In addition, recent genetic studies have linked Ca2þ channel
subunits to several animal seizure models and human neuro-
logical disorders [2,3]. Ca2þ channels are heteromultimers,
consisting at least of a main K1 subunit and auxiliary K2N,
L and Q subunits. The K1 subunit is a transmembrane protein
that forms the ion-conducting pore and the auxiliary L sub-
unit is an intracellular protein that is thought to play impor-
tant roles in channel regulation [4]. The auxiliary K2N and
Q subunits are transmembrane proteins also involved in the
regulation of the basic biophysical properties and surface ex-
pression of Ca2þ channel [5].
Gabapentin (GBP) is a synthetic drug that has shown anti-
convulsant activity in a variety of animal seizure models and
is also e¡ective in the treatment of human partial and gener-
alized tonic-clonic seizures [1,6,7] ; however, the anticonvul-
sant mechanism of GBP is not known. Despite its structural
relationship to the Q-aminobutyric acid (GABA), GBP does
not possess a high a⁄nity for GABA receptors [8], and does
not a¡ect the uptake or the degradation of this inhibitory
neurotransmitter [6,7]. On the other hand, GBP has been
shown to be the substrate for a speci¢c binding site in the
brain [8], and is capable of modifying the electrophysiological
properties of central neurons in culture after prolonged but
not brief exposure at concentrations used in clinical trials [9].
A high-a⁄nity GBP-binding protein puri¢ed from brain mem-
branes has been characterized, and identi¢ed to be the K2N
subunit of the Ca2þ channel by N-terminal sequencing [10].
Likewise, transient transfection of the K2N cDNA in COS-7
cells signi¢cantly increased GBP binding, consistent with the
expression of the K2N protein as measured by Western blotting
[10].
In this report we examined the consequences of the chronic
treatment with GBP on the plasma membrane Ca2þ conduc-
tances and on the integrity of the Ca2þ channel complex. Our
results show an alteration in neuronal P/Q-type Ca2þ channel
activity after chronic treatment with GBP presumably caused
by a direct e¡ect of the drug on the molecular channel con-
¢guration.
2. Materials and methods
2.1. Materials and preparation of oocytes
g-Conotoxin GVIA, g-Conotoxin MVIIC (Peptides International
Inc., Louisville, KY, USA) and GBP [1-(aminomethyl) cyclohexane
acetic acid, Neurontin0, Parke-Davis Pharmaceuticals Ltd.] were pre-
pared as stock in distilled water and aliquots were store at 320‡ C.
All other chemicals were of reagent grade. Xenopus laevis oocytes were
prepared as described previously [14].
2.2. Heterologous expression of Ca2+ channel subunits
cDNA clones used were as follows: rabbit brain CaV2.1 (K12.1;
formerly K1A) [11], rat brain CaVL3 [12], rat brain CaVK2N-1 [13].
As expression vectors, pcDNA3 (Invitrogen, Carlsbad, CA, USA)
was used for CaVK2N-1, pSP72 (Promega, Madison, WI, USA) for
CaV2.1, and pGEM3 (Promega) for CaVL3. Linearization of those
plasmids, in vitro transcription, cRNA puri¢cation, and injection of
cRNA were performed as described previously [14]. Injected oocytes
were incubated at 18‡C for 4 days with or without GBP before elec-
trophysiological recording.
2.3. Electrophysiological recordings and data analyses
Ba2þ currents through Ca2þ channels were recorded by the two-
electrode voltage-clamp (TEV) technique [15] as described previously
[14]. Brie£y, both voltage and current electrodes were ¢lled with 3 M
KCl and had initial tip resistances of 0.5^1.0 M6. The recording
chamber was ¢lled with recording solution containing 10 Ba2þ(OH)2
mM. Test potentials were applied for 500 ms from a holding potential
of 390 mV and the results were analyzed by pClamp 6 (Axon Instru-
ments) and SigmaPlot 4.01 (SPSS Inc., Chicago, IL, USA).
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2.4. Partial puri¢cation of native Ca2+ channels and GBP treatment
Ca2þ channel complex was partially puri¢ed from rabbit skeletal
muscle and brain as described previously [14]. Brie£y, from 50 mg of
microsomes, the Ca2þ channel complexes were extracted from micro-
somes with solubilization bu¡er containing 1% digitonin (Biochemica
and Synthetica, Switzerland). Out of the solubilized proteins, Ca2þ
channel complexes were then enriched through wheat germ aggluti-
nin^agarose a⁄nity chromatography (Vector Laboratories, Burlin-
game, CA, USA). The puri¢ed channel complexes were then incuba-
ted with or without 1.0 mM GBP at 4‡C overnight in a solution
containing (in mM) 50 Tris^HCl, pH 7.4, 200 NaCl, a mixture of
protease inhibitors, and 0.1% Tween-20 (Fisher Scienti¢c). Similar
experiments were also performed with di¡erent incubation conditions
such as various concentration of GBP, 0.1% digitonin instead of 0.1%
Tween-20, and room temperature for 1 h instead of 4‡C overnight.
2.5. Antibodies and Western blot analysis
Antibodies, IIID5E1, Guinea Pig 1, Sheep 6, and Guinea Pig 16,
speci¢c for the Ca2þ channel subunits, K11.1, K2, L1a, and Q1, respec-
tively, have been described previously [16^19]. Western blot analysis
was performed as described previously [14].
2.6. Statistical analysis
Each experiment was repeated at least three times using di¡erent
animals. Data are presented as meanRS.E.M. and the number of
oocytes is indicated in ¢gures and text. Probability (P) of 0.05 or
less was considered signi¢cant.
3. Results
3.1. Acute treatment with GBP does not a¡ect Ca2+ channel
activity
GBP exhibits high-a⁄nity binding activity to the K2N sub-
unit of Ca2þ channels; however, the link between GBP bind-
ing and channel function remains to be clari¢ed. Though
some functional studies have shown a modest inhibitory e¡ect
of GBP on neuronal Ca2þ currents in mammalian cultured
cells, most of previous data are based on native currents
where the expression of di¡erent isoforms of K2N has pro-
duced inconsistent results. We therefore decided to further
investigate the actions of GBP on neuronal recombinant
Ca2þ channels expressed in Xenopus oocytes using the TEV
technique. We ¢rst analyzed the e¡ects of the acute applica-
tion of GBP on the recombinant P/Q-type currents expressed
in oocytes after cRNA injection of Ca2þ channel subunits
(K12.1/L3/K2N-1). Fig. 1A shows normalized peak Ba2þ current
(IBa) amplitude levels of two oocytes in response to a depo-
larizing step to 0 mV from a holding potential of 390 mV
plotted against time. The e¡ects of GBP were then tested on
IBa elicited by the test potential. As can be seen, GBP at a
concentration of 30 WM had no e¡ect on the peak amplitude
or in the kinetics of the expressed current (Fig. 1B). Peak
current amplitude of the K12.1/L3/K2N-1 channels was
31952R 497 nA (n=8) and 31908R 276 nA (n=9) with or
without GBP treatment, respectively. To ensure that the neg-
ative result with GBP was not due to a lack of access of GBP
to its binding site, distinct Ca2þ channel blockers were added
to the recording chamber. Under these circumstances, current
amplitude was again una¡ected by the N-type Ca2þ channel
antagonist g-Ctx GVIA. In contrast, IBa was signi¢cantly
reduced by the speci¢c P/Q-type Ca2þ channel blocker
g-Ctx MVIIC and by a non-speci¢c blocker (CdCl2) con¢rm-
ing that the recombinant P/Q-type expressed in our system
were not sensitive to the acute e¡ects of GBP (Fig. 1A).
Lastly, the properties of the current^voltage relation of the
IBa elicited by voltage steps from 340 to +40 mV with a
holding potential of 390 mV (not shown) in the presence of
GBP were very similar to those in the absence of the drug
(V1=2 of 312.8 and 313.6 mV, respectively).
3.2. Chronic e¡ect of GBP on Ca2+ channels
Having shown that the acute treatment with GBP does not
a¡ect the activity of recombinant Ca2þ channels, we next
examined the potential e¡ects of the chronic exposure to
GBP on the fundamental biophysical properties of channels
expressed in oocytes. Treatment with 30 WM GBP for 4 days
did not seem to have a major e¡ect on peak current amplitude
at all voltages tested (not shown); however, it had a signi¢-
cant impact on the waveform. As shown in Fig. 2, IBa re-
corded from oocytes expressing P/Q-type Ca2þ channels
showed considerable time-dependent inactivation following
the peak. To examine a potential e¡ect of GBP treatment
on Ca2þ channel inactivation, the test pulses to 310 and
0 mV eliciting maximum currents were selected to compare
the kinetics of inactivation (Fig. 2A). For every trace, IBa was
normalized to the peak amplitude and the decay was further
analyzed by single exponential functions. The results of this
analysis showed that in control cells the current during 500 ms
pulses decayed with a time constant (d) of 200R 12 and
190R 12 ms at 310 and 0 mV, respectively. As shown in
Fig. 1. P/Q-type current in oocytes is insensitive to the acute e¡ects
of GBP. A: Representative time courses of block by 200 WM CdCl2
and 1 WM g-Ctx MVIIC of the P/Q-type (K12.1/L3/K2N-1) currents
expressed in two individual oocytes (open and ¢lled circles). Cur-
rents were elicited by stepping from a holding potential of 390 mV
to a test potential of 0 mV and normalized to the peak amplitude.
Note that in both cases currents were insensitive to the acute appli-
cation of g-Ctx GVIA (1 WM) and GBP (30 WM). B: Representa-
tive IBa traces before (1), during application of GBP (2) and after
addition of 200 WM of CdCl2 (3) to the external recording solution.
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Fig. 2B, current inactivation in GBP treated cells was signi¢-
cantly slower at all voltages tested (e.g. d=256R 13 and
249R 14 ms at 310 and 0 mV). Notably, the time course of
the currents recorded in cells expressing recombinant channels
lacking K2N was not a¡ected by GBP treatment, suggesting
that K2N is essential for the e¡ect of the drug on channel
inactivation (Fig. 2A,B). In addition, one of the concerns
when analyzing macroscopic currents in the oocyte system is
that the density of the expressed channels may alter the ki-
netics of the currents. Fig. 2C summarizes the results obtained
in a number of control and GBP treated oocytes from di¡er-
ent batches, and expressing a di¡erent Ca2þ channel subunit
composition. At 0 mV, IBa amplitudes had a six-fold range
(3571 to 33730 nA); however, these cells with large di¡er-
ences in channel expression had similar rates of inactivation
(1/d), suggesting that at least over this range of current, the
rate of inactivation is independent of the channel density.
Fig. 2. Evidence for regulation of P/Q-type Ca2þ channels current
in oocytes after chronic treatment with GBP. A: Representative
traces of IBa through recombinant P/Q-type channels recorded in
the presence and absence of GBP at 0 mV and scaled to the same
amplitude. B: A single exponential was used to ¢t IBa decay to gen-
erate the relationship between the time constant, d, of inactivation
and the test potential. The curve was obtained by applying 500 ms
voltage pulses in the range of from 310 to +30 mV. C: Compari-
son of the rates of inactivation (1/d) plotted with respect to peak
current at 0 mV in oocytes expressing di¡erent CaV subunit compo-
sition: a K12.1/L3 ; b K12.1/L3/K2N ; E K12.1/L3+GBP; F K12.1/L3/
K2N+GBP.
Fig. 3. The decrease in current inactivation by GBP was dose de-
pendent. A: Representative traces of IBa through recombinant P/Q-
type Ca2þ channels (K12.1/L3/K2N-1) recorded at 0 mV and scaled to
the same amplitude. Oocytes were treated for 4 days with GBP as
listed. B: Averaged voltage dependence of IBa inactivation kinetics
in cells chronically treated with di¡erent concentrations of GBP.
Time constants were determined by ¢tting IBa traces sampled in the
range of 310 to +30 mV and then plotted as function of test poten-
tials. C: Concentration/response curve for the slowing of IBa inacti-
vation by GBP (meanRS.E.M., n=6^9). The current was evoked
by a voltage pulse from the holding potential of 390 to 0 mV.
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The graphs on Fig. 3 show the e¡ect of di¡erent concen-
trations of GBP (300 nM to 1 mM) on the time constant of
current inactivation. In Fig. 3A, representative normalized
current traces to determine the time course of inactivation
are compared at the potential of 0 mV, and the values ob-
tained for the inactivation time constants in di¡erent cells are
plotted versus membrane voltage in Fig. 3B. The d for IBa in
control cells was in the range ofV160^200 ms and showed no
apparent voltage dependence in the 310^30 mV range. Nota-
bly, a decrease of the decay kinetics of the current seemed to
be an important e¡ect of the drug treatment, as re£ected in
the concentration/response curve in Fig. 3C, which shows how
the time constant for the inactivating component of IBa at
0 mV increased as a function of increasing GBP concentra-
tions from a value of 201R 6 ms in the cells treated with 300
nM to 274R 7 ms in the cells exposed to 1 mM of the drug
(Fig. 3C).
3.3. GBP seems not to a¡ect the integrity of the Ca2+ channel
complex
Since the inactivation kinetics of GBP treated cells closely
resembled that of cells expressing channels lacking K2N, we
hypothesized that GBP binding could cause an alteration in
the integrity of the Ca2þ channel complex. To test this hy-
pothesis, we investigated the potential dissociation of subunits
including K2N from the channel complex through partial pu-
ri¢cation, GBP treatment (1.0 mM), and sucrose gradient
fractionation. Western blot analysis of sucrose gradient frac-
tions with anti-K11.1, K2, L1a, and Q1 antibodies showed that
the co-sedimentation of all these subunits in fractions 7^10
without GBP treatment (Fig. 4A). Interestingly, as shown in
Fig. 4B, the co-sedimentation of Ca2þ channel subunits was
not signi¢cantly a¡ected by GBP treatment. None of the Ca2þ
channel subunits including K2N was apparently dissociated
from the complex by the treatment, suggesting that GBP
Fig. 4. GBP treatment does not alter the integrity of the Ca2þ channel complex. A,B: Sucrose gradient fractionation of partially puri¢ed skele-
tal Ca2þ channels with (B) or without (A) 1 mM GBP treatment. Equal volume of proteins (100 Wl) were loaded in each lane. After transfer of
gels into membranes, the blots were cut and probed separately with a⁄nity-puri¢ed antibodies against the subunits of the Ca2þ channel. The
numbers at the top indicate the fraction of the sucrose gradient from top to bottom. The identity of each band is indicated at the right side of
panels. Molecular mass standards (U1033) are indicated on the left.
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binding does not disrupt the channel complex. We also tried
di¡erent incubation conditions of GBP treatment such as var-
ious concentrations of the drug, incubation time, and temper-
ature. In none of these experimental conditions, we could
observe any appreciable change in the Ca2þ channel complex
integrity by the drug treatment (data not shown). Lastly, sim-
ilar experiments using partially puri¢ed Ca2þ channel com-
plexes from rabbit brain showed that the treatment with
GBP has no e¡ect also on the integrity of native neuronal
Ca2þ channels (data not shown).
4. Discussion
In spite of the demonstrated direct interaction between
GBP and the Ca2þ channel K2N subunit [10], controversial
results regarding the functional e¡ects of the drug on Ca2þ
channels have been reported. No appreciable e¡ects of the
acute treatment with GBP on native currents recorded from
human hippocampal granulose cells [20] and PC12 cells [21]
have been found. On the other hand, acute application of
GBP has been shown to inhibit L-type Ca2þ currents in iso-
lated rat neurons [22], mouse skeletal myotubes [23], and neu-
ronal N-type currents in cultured rat dorsal root ganglion
neurons [24].
Most of the previous functional assays studying the e¡ects
of GBP on Ca2þ channel activity have been performed after
acute exposure to the drug. Nevertheless, previous animal in-
vestigations have suggested that GBP should be transported
across the plasma membrane of the neurons to exert its e¡ect,
and interestingly, the antiepileptic e¡ect of GBP peaked at a
time when the brain interstitial level of the drug, as well as its
plasma concentration, had declined signi¢cantly [25]. Further-
more, previous studies have shown that GBP is actively ab-
sorbed by the cells via the system L-amino acid transporter
[26]. In this context, the present study focused on testing the
potential chronic e¡ects of GBP on neuronal Ca2þ channel
activity.
Our results show that GBP deeply a¡ected the kinetics of
channel inactivation after chronic exposure to the drug. No-
tably, several studies have shown that alteration in the inacti-
vation properties of Ca2þ channels is an important mechanism
for K2N regulation of ionic current [27,28]. In addition, con-
versely to what happens with the acute GBP treatment where
no alterations in the activity of the channels was observed, the
data of the chronic treatment may be better explained by an
intracellular interaction between K2N and GBP during the pro-
cess of channel assembly, possibly modifying the association
of the auxiliary subunit with the channel complex. Therefore,
by using partially puri¢ed Ca2þ channels, we tested whether
GBP could alter the integrity of the native Ca2þ channel com-
plex. However, as shown in Fig. 4, none of the Ca2þ channel
subunits including K2N was dissociated from the complex al-
ready formed by the overnight treatment with GBP. Together,
the electrophysiological and biochemical analyses in this study
suggest that the chronic e¡ects of GBP on the inactivation
kinetics of Ca2þ channel could be explained by an alteration
of the K2N actions on the properties of the Ca2þ channels
possibly by the induction of a conformational change in the
channel, although this alteration might not be large enough to
cause the dissociation of K2N from the channel complex.
Our results, however, do not rule out the presence of acute
e¡ects of GBP on neuronal Ca2þ channels. Acute GBP treat-
ment might introduce subtle alterations on the properties of
the channels that are not apparent under some experimental
conditions or are not easily detected in large currents such as
those expressed in the oocytes system. Therefore, a combina-
tion of intracellular and extracellular interaction (after chronic
and acute treatment, respectively) between K2N and GBP
could be seen as complementary mechanisms of channel reg-
ulation. In addition, we could speculate that the change of
inactivation kinetics by chronic treatment with GBP could
not be observed in cultured mammalian cells [21] due to the
fact that they are generally keep in L-glutamine-containing
culture media. The concentration of L-glutamine could be
high enough to saturate the amino acid transporter system
in the cells and GBP may not be e⁄ciently translocated to
the interior of the cells. Actually, it was recently reported that
GBP could compete with some amino acids for the transpor-
tation by the L-type amino acid transporter 1 [29] that has
been shown to be a pathway for concentrating GBP intracel-
lularly [26]. In contrast, oocytes are kept in culture in an
amino acid-free medium. In this case, the availability of the
transporter would be high and the translocation of the drug to
the cytoplasm would occur normally. Furthermore, the dis-
crepancy between the data obtained in mammalian cells and
oocytes might be also explained by the fact that only K2N-1
and K2N-2 isoforms (but not K2N-3) bind to GBP [30,31] but
all three isoforms are expressed di¡erentially in the brain [32].
This may indicate the presence of an exquisite sensitivity to
GBP that is dependent on neuronal type and/or localization
as well as in Ca2þ channel K2N isoform expression.
Lastly, being GBP the ¢rst ligand that interacts with the
K2N subunit, demonstration of a direct regulation of neuronal
Ca2þ channels by the drug may be important to the under-
standing of its antiepileptic properties. Experimental evidence
indicates that the epileptic discharges, generated when a phys-
iological tonic mode of neuronal ¢ring shifts to a burst-¢ring
mode [33], are produced by aberrant thalamocortical oscilla-
tions [34]. P/Q-type Ca2þ channels are present and play a role
in neurotransmitter release in thalamic neurons [35] providing
a potential mechanistic link between Ca2þ currents and tha-
lamocortical circuits. Interestingly, a reduction of excitatory
synaptic transmission in the thalamus of epileptic mice has
been documented [36] as a result of reduced Ca2þ in£ux,
and it was proposed that a net enhanced GABAergic input
in thalamocortical neurons may synchronize them into a
burst-¢ring mode. In addition, several studies have revealed
that some paroxysmal disorders including epilepsy are linked
to Ca2þ channel mutations leading to reduced Ca2þ currents
in cerebellar neurons of mice and humans [2,3]. Therefore, it
is tempting to speculate that one of the consequences of the
chronic treatment with GBP may be to revert this increasing
Ca2þ in£ux by slowing down neuronal Ca2þ channel inacti-
vation, though further studies will be needed to unveil the
precise molecular mechanisms of GBP antiepileptic action.
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